中東およびアフリカの凍結乾燥注射薬市場 – 業界動向と2028年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

中東およびアフリカの凍結乾燥注射薬市場 – 業界動向と2028年までの予測

  • Pharmaceutical
  • Published Report
  • Jun 2021
  • MEA
  • 350 ページ
  • テーブル数: 188
  • 図の数: 48

>中東およびアフリカの凍結乾燥注射薬市場、包装別(バイアル、デュアルチャンバーシリンジ、デュアルチャンバーカートリッジなど)、薬物クラス別(抗感染薬、抗腫瘍薬、利尿薬、プロトンポンプ阻害薬、麻酔薬、抗凝固薬、NSAID、コルチコステロイドなど)、形態別(粉末および液体)、適応症別(腫瘍学、自己免疫疾患、ホルモン障害、呼吸器疾患、胃腸疾患、皮膚疾患、眼科疾患など)、投与経路別(静脈内/点滴、筋肉内など)、エンドユーザー別(病院、診療所、在宅医療など)、流通チャネル別(直接入札、小売販売など)、国別(サウジアラビア、南アフリカ、UAE、イスラエル、クウェート、エジプト、その他の中東およびアフリカ)業界動向および2025年までの予測2028年。

中東およびアフリカの凍結乾燥注射薬市場

市場分析と洞察: 中東およびアフリカの凍結乾燥注射薬市場

凍結乾燥注射薬市場は、2021年から2028年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に4.2%のCAGRで成長し、2028年までに2億814万米ドルに達すると分析しています。世界中で慢性的な健康状態が増加していることが、凍結乾燥注射薬市場の需要を押し上げる原動力となることが予想されます。

フリーズドライは凍結乾燥の別名です。これは、溶液を真空下で凍結および蒸発させることにより、溶媒から固体材料を分離する技術です。凍結乾燥製品は、従来の医薬品よりも保存期間が長いと考えられているため、好まれています。生物製剤、タンパク質、抗体微生物、非経口薬、血漿、酵素、診断試薬、ワクチン、および栄養補助食品の保護は、通常、凍結乾燥によって行われます。不安定なバルク成分を安定に保つには、滅菌注射剤の凍結乾燥が必要です。

凍結乾燥注射薬の技術進歩の進展は、凍結乾燥注射薬市場の需要を押し上げる原動力となることが期待されています。凍結乾燥薬の製品リコール数の増加とパッケージの種類の増加は、凍結乾燥注射薬市場の抑制要因となることが予想されます。凍結乾燥薬の規制承認の増加は、凍結乾燥注射薬市場の需要を押し上げる機会となることが予想されます。非経口製品用の凍結乾燥バイアルの製造に関連する要因は、凍結乾燥注射薬市場の需要に悪影響を及ぼすことが予想されます。

凍結乾燥注射薬市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と凍結乾燥注射薬市場のシナリオを理解するには、アナリスト概要について Data Bridge Market Research にお問い合わせください。当社のチームが、希望する目標を達成するための収益影響ソリューションの作成をお手伝いします。

中東およびアフリカの凍結乾燥注射薬市場

凍結乾燥注射薬市場の範囲と市場規模

凍結乾燥注射薬市場は、包装、薬物クラス、形態、適応症、投与経路、エンドユーザー、流通チャネルに基づいて、7 つの主要なセグメントに分類されます。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コア アプリケーション領域とターゲット市場の違いを決定するのに役立ちます。

  • 包装に基づいて、凍結乾燥注射薬市場は、バイアル、デュアルチャンバーシリンジ、デュアルチャンバーカートリッジ、その他に分類されます。 2021年には、凍結乾燥注射薬のほとんどがバイアルに包装されているため、バイアルセグメントが凍結乾燥注射薬市場を支配すると予想されており、市場で影響力があり、成長しています。
  • 薬剤クラスに基づいて、凍結乾燥注射薬市場は、抗感染薬、抗腫瘍薬、利尿薬、プロトンポンプ阻害剤、麻酔薬、抗凝固薬、NSAID、コルチコステロイドなどに分類されます。2021年には、世界中で抗生物質と抗ウイルス薬の需要が増加しているため、抗感染セグメントが凍結乾燥注射薬市場を支配すると予想されます。
  • 形態に基づいて、凍結乾燥注射薬市場は粉末と液体に分類されます。2021年には、世界中での保管と輸送が容易で安全なため、粉末セグメントが凍結乾燥注射薬市場を支配すると予想されます。
  • 適応症に基づいて、凍結乾燥注射薬市場は、腫瘍学、自己免疫疾患、ホルモン障害、呼吸器疾患、胃腸障害、皮膚疾患、眼科疾患、その他に分類されます。 2021年には、腫瘍学用の凍結乾燥注射薬の数が増えるため、腫瘍学セグメントが凍結乾燥注射薬市場を支配すると予想されます。
  • 投与経路に基づいて、凍結乾燥注射薬市場は、静脈内/点滴、筋肉内、その他に分類されます。2021年には、この投与経路による薬物の100%の生物学的利用能のため、静脈内/点滴セグメントが凍結乾燥注射薬市場を支配すると予想されます。
  • エンドユーザーに基づいて、凍結乾燥注射薬市場は、病院、診療所、在宅医療、その他に分類されます。2021年には、病院が豪華な機器を購入する財政能力と、それらを投与するための訓練を受けた専門家の存在により、病院セグメントが凍結乾燥注射薬市場を支配すると予想されます。
  • 流通チャネルに基づいて、凍結乾燥注射薬市場は、直接入札、小売販売、その他に分類されます。2021年には、ほとんどのサービスプロバイダーが凍結乾燥注射薬を製造業者から購入し、直接販売からの収益が高いことが注目されているため、直接入札セグメントが凍結乾燥注射薬市場を支配すると予想され、市場で影響力があり成長しています。

中東およびアフリカの凍結乾燥注射薬市場の国別分析

中東およびアフリカの凍結乾燥注射薬市場が分析され、市場規模の情報が、上記の国、包装、薬物クラス、形態、適応症、投与経路、エンドユーザー、流通チャネル別に提供されます。

中東およびアフリカの凍結乾燥注射薬市場に含まれる国は、サウジアラビア、南アフリカ、UAE、イスラエル、クウェート、エジプト、およびその他の中東およびアフリカの国々です。

サウジアラビアは、主要な市場プレーヤーの存在と同地域における技術進歩の加速により、中東およびアフリカの凍結乾燥注射薬市場で優位に立つと予想されています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、中東およびアフリカのブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。 

メーカーによる新製品の発売は、凍結乾燥注射薬市場のプレーヤーに新たな機会を生み出しています。

凍結乾燥注射薬市場では、凍結乾燥注射薬市場の売上、凍結乾燥注射薬市場の進歩の影響、凍結乾燥注射薬市場へのサポートに関する規制シナリオの変化など、凍結乾燥注射薬業界の各国の成長に関する詳細な市場分析も提供しています。データは、2010年から2019年までの履歴期間で利用可能です。 

競争環境と凍結乾燥注射薬の市場シェア分析

凍結乾燥注射薬市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、中東およびアフリカの凍結乾燥注射薬市場に関連する会社の焦点にのみ関連しています。

中東およびアフリカの凍結乾燥注射薬市場レポートで取り上げられている主要企業は、Genex Pharma、Aristopharma Ltd.、Pfizer Inc.、Viatris Inc.、Gilead Sciences, Inc.、Jubilant Generics Limited – A Jubilant Pharma Company、Novartis AG、Otsuka America Pharmaceutical, Inc.、Zydus Cadila、Cipla Inc.、Merck Sharp & Dohme Corp. (Merck & Co., Inc. の子会社)、Sanofi、Celon Laboratories Pvt. Ltd.、Baxter などの国内企業です。DBMR のアナリストは、競争力を理解し、各競合他社の競合分析を個別に提供します。

世界中の企業によって多くの契約や協定も開始されており、凍結乾燥注射薬市場の拡大も加速しています。

  • 2019年11月、ファイザー社は、アップジョンという事業部がマイラン社と合併し、ビアトリス社という新会社を設立したことを発表しました。同社の事業部とマイラン社との統合により、製品ポートフォリオが拡大し、市場での製品需要の増加につながっています。

市場プレーヤーによるコラボレーション、ジョイントベンチャー、その他の戦略により、凍結乾燥注射薬市場における企業市場が強化され、組織にとっても凍結乾燥注射薬市場への提供を改善するメリットがもたらされます。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PACKAGING LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: REGULATORY FRAMEWORK

5 EPIDEMIOLOGY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN CHRONIC HEALTH CONDITIONS

6.1.2 SAFE TRANSIT AND STORAGE OF THESE SUBSTANCES UNTIL THEIR END-USE

6.1.3 INCREASE IN GERIATRIC POPULATION WITH CHRONIC DISEASES

6.1.4 EXPANSION OF PIPELINE OF LYOPHILIZED INJECTABLE DRUGS

6.1.5 TECHNOLOGICAL ADVANCEMENTS

6.2 RESTRAINTS

6.2.1 RISK OF NEEDLESTICK INJURIES

6.2.2 INCREASE IN NUMBER OF PRODUCT RECALLS FOR LYOPHILIZED DRUGS AND PACKAGING TYPE

6.3 OPPORTUNITIES

6.3.1 RISE IN REGULATORY APPROVALS FOR LYOPHILIZED DRUGS

6.3.2 STRATEGIC INITIATIVES OF KEY MARKET PLAYERS

6.3.3 QUALITY CONCERNS

6.4 CHALLENGES

6.4.1 CHALLENGES ASSOCIATED WITH MANUFACTURING LYOPHILIZED VIALS FOR PARENTERAL PRODUCTS

6.4.2 TIME-CONSUMING PROCESS AND HIGH COST

7 IMPACT OF COVID-19 ON THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT IN DEMAND

7.3 IMPACT ON SUPPLY

7.4 STRATEGIC INITIATIVE

7.5 CONCLUSION

8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING

8.1 OVERVIEW

8.2 VIALS

8.3 DUAL-CHAMBER SYRINGES

8.4 DUAL-CHAMBER CARTRIDGES

8.5 OTHERS

9 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS

9.1 OVERVIEW

9.2 ANTI-INFECTIVE’S

9.2.1 ANTIBIOTICS

9.2.1.1 Azithromycin

9.2.1.2 Doxycycline

9.2.1.3 Vancomycin

9.2.1.4 Polymyxin B

9.2.1.5 Piperacillin

9.2.1.6 Tazobactam

9.2.1.7 Others

9.2.2 ANTIFUNGAL

9.2.2.1 Mycamine

9.2.2.2 Caspofungin Acetate

9.2.2.3 Isavuconazonium Sulfate

9.2.2.4 Amphotericin

9.2.2.5 Others

9.2.3 ANTIVIRAL

9.2.3.1 Acyclovir

9.2.3.2 Ganciclovir

9.2.3.3 Remdesivir

9.2.3.4 Others

9.2.4 OTHERS

9.3 ANTINEOPLASTIC

9.3.1 METHOTREXATE

9.3.2 GEMCITABINE

9.3.3 CYTARABINE

9.3.4 FLUDARABINE

9.3.5 DOXORUBICIN

9.3.6 OXALIPLATIN

9.3.7 ZOLEDRONIC ACID

9.3.8 OTHERS

9.4 DIURETICS

9.4.1 CHLOROTHIAZIDE

9.4.2 ETHACRYNIC ACID

9.4.3 ACETAZOLAMIDE

9.4.4 OTHERS

9.5 PROTON PUMP INHIBITOR

9.5.1 ESOMEPRAZOLE SODIUM

9.5.2 PANTOPRAZOLE SODIUM

9.5.3 OMEPRAZOLE

9.5.4 OTHERS

9.6 ANESTHETIC

9.6.1 VECURONIUM BROMIDE

9.6.2 SODIUM THIOPENTAL

9.6.3 LIDOCAINE

9.6.4 OTHERS

9.7 ANTICOAGULANT

9.7.1 COUMADIN

9.7.2 UROKINASE

9.7.3 ANTITHROMBIN (RECOMBINANT)

9.7.4 APIXABAN

9.7.5 RIVAROXABAN

9.7.6 OTHERS

9.8 NSAID’S

9.8.1 INDOMETHACIN

9.8.2 IBUPROFEN

9.8.3 DICLOFENAC

9.8.4 KETOROLAC

9.8.5 OTHERS

9.9 CORTICOSTEROIDS

9.9.1 HYDROCORTISONE

9.9.2 METHYLPREDNISOLONE

9.9.3 OTHERS

9.1 OTHERS

10 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM

10.1 OVERVIEW

10.2 POWDER

10.3 LIQUID

11 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION

11.1 OVERVIEW

11.2 ONCOLOGY

11.3 AUTOIMMUNE DISEASES

11.4 HORMONAL DISORDERS

11.5 RESPIRATORY DISEASES

11.6 GASTROINTESTINAL DISORDERS

11.7 DERMATOLOGICAL DISORDERS

11.8 OPHTHALMIC DISEASES

11.9 OTHERS

12 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 INTRAVENOUS/INFUSION

12.3 INTRAMUSCULAR

12.4 OTHERS

13 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 HOME HEALTHCARE

13.5 OTHERS

14 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDERS

14.3 RETAIL SALES

14.4 OTHERS

15 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION

15.1 MIDDLE EAST & AFRICA

15.1.1 SOUTH AFRICA

15.1.2 SAUDI ARABIA

15.1.3 U.A.E.

15.1.4 EGYPT

15.1.5 KUWAIT

15.1.6 ISRAEL

15.1.7 REST OF MIDDLE EAST & AFRICA

16 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 PFIZER INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS KABI AG)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 CIPLA INC.

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 NOVARTIS AG

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 BAXTER

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENTS

18.7 ZYDUS CADILA

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 AFFY PHARMA PVT LTD.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 AMNEAL PHARMACEUTICALS LLC

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENTS

18.1 ARISTOPHARMA LTD.

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 ASTELLAS PHARMA US, INC. (A SUBSIDIARY OF ASTELLAS PHARMA INC.)

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 AUROMEDICS PHARMA LLC (A SUBSIDIARY OF AUROBINDO PHARMA)

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 CELON LABORATORIES PVT.LTD.

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENT

18.14 CIRONDRUGS

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 GENEX PHARMA

18.15.1 COMPANY SNAPSHOT

18.15.2 PRODUCT PORTFOLIO

18.15.3 RECENT DEVELOPMENT

18.16 GILEAD SCIENCES, INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 REVENUE ANALYSIS

18.16.3 PRODUCT PORTFOLIO

18.16.4 RECENT DEVELOPMENTS

18.17 JUBILANT GENERICS LIMITED – A JUBILANT PHARMA COMPANY

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENTS

18.18 OTSUKA AMERICA PHARMACEUTICAL, INC

18.18.1 COMPANY SNAPSHOT

18.18.2 PRODUCT PORTFOLIO

18.18.3 RECENT DEVELOPMENTS

18.19 SANOFI

18.19.1 COMPANY SNAPSHOT

18.19.2 REVENUE ANALYSIS

18.19.3 PRODUCT PORTFOLIO

18.19.4 RECENT DEVELOPMENT

18.2 VIATRIS INC.

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

表のリスト

TABLE 1 PIPELINE LYOPHILIZED INJECTABLE DRUGS

TABLE 2 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA VIALS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA DUAL-CHAMBER SYRINGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA DUAL-CHAMBER CARTRIDGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 9 MIDDLE EAST AND AFRICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA ANESTHETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA POWDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA LIQUID IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA ONCOLOGY IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA HORMONAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA RESPIRATORY DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA DERMATOLOGICAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA OPHTHALMIC DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA INTRAVENOUS/INFUSION IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA INTRAMUSCULAR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA HOSPITAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA CLINICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA DIRECT TENDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA RETAIL SALES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 58 MIDDLE EAST & AFRICA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 67 MIDDLE EAST & AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 68 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 69 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 70 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 71 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 75 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 76 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 77 SOUTH AFRICA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 78 SOUTH AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 79 SOUTH AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 80 SOUTH AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 81 SOUTH AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 82 SOUTH AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 83 SOUTH AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 84 SOUTH AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 85 SOUTH AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 86 SOUTH AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 87 SOUTH AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 88 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 89 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 90 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 91 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 93 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 94 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 95 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 96 SAUDI ARABIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 97 SAUDI ARABIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 98 SAUDI ARABIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 99 SAUDI ARABIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 100 SAUDI ARABIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 101 SAUDI ARABIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 102 SAUDI ARABIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 103 SAUDI ARABIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 104 SAUDI ARABIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 105 SAUDI ARABIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 106 SAUDI ARABIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 107 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 108 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 109 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 110 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 111 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 112 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 113 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 114 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 115 U.A.E. ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 116 U.A.E. ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 117 U.A.E. ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 118 U.A.E. ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 119 U.A.E. ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 120 U.A.E. DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 121 U.A.E. PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 122 U.A.E. ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 123 U.A.E. ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 124 U.A.E. NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 125 U.A.E. CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 126 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 127 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 128 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 129 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 130 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 131 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 132 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 133 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 134 EGYPT ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 135 EGYPT ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 136 EGYPT ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 137 EGYPT ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 138 EGYPT ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 139 EGYPT DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 140 EGYPT PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 141 EGYPT ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 142 EGYPT ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 143 EGYPT NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 144 EGYPT CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 145 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 146 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 147 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 148 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 149 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 150 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 151 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 152 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 153 KUWAIT ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 154 KUWAIT ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 155 KUWAIT ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 156 KUWAIT ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 157 KUWAIT ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 158 KUWAIT DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 159 KUWAIT PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 160 KUWAIT ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 161 KUWAIT ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 162 KUWAIT NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 163 KUWAIT CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 164 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 165 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 166 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 167 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 168 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 169 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 170 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 171 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 172 ISRAEL ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 173 ISRAEL ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 174 ISRAEL ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 175 ISRAEL ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 176 ISRAEL ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 177 ISRAEL DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 178 ISRAEL PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 179 ISRAEL ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 180 ISRAEL ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 181 ISRAEL NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 182 ISRAEL CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 183 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 184 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 185 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 186 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 187 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 188 REST OF MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

図表一覧

FIGURE 1 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 11 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET

FIGURE 15 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020

FIGURE 16 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)

FIGURE 17 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)

FIGURE 18 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE

FIGURE 19 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020

FIGURE 20 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)

FIGURE 21 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)

FIGURE 22 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE

FIGURE 23 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020

FIGURE 24 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)

FIGURE 25 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)

FIGURE 26 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE

FIGURE 27 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020

FIGURE 28 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 29 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 30 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 31 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

FIGURE 33 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 34 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020

FIGURE 36 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 37 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 38 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 40 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 41 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 42 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)

FIGURE 44 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)

FIGURE 45 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 46 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 47 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING (2021-2028)

FIGURE 48 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Middle East and Africa Lyophilized Injectable Drugs Market size will be worth USD 208.14 million by 2028.
The Middle East and Africa Lyophilized Injectable Drugs Market growth rate will be 4.2% by 2028.
Growing technological advancement of the lyophilized injectable drugs and Rise in number of product recalls for lyophilized drugs and packaging type are the growth drivers of the Middle East and Africa Lyophilized Injectable Drugs Market.
The packaging, drug class, form, indication, route of administration, end user and distribution channel are the factors on which the Middle East and Africa Lyophilized Injectable Drugs Market research is based.
The major companies in the Middle East and Africa Lyophilized Injectable Drugs Market are Genex Pharma, Aristopharma Ltd., Pfizer Inc., Viatris Inc., Gilead Sciences, Inc., Jubilant Generics Limited – A Jubilant Pharma Company, Novartis AG, Otsuka America Pharmaceutical, Inc., Zydus Cadila, Cipla Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Sanofi, Celon Laboratories Pvt. Ltd. and Baxter